T1	tradename 0 9	Krystexxa
T3	nanoparticle 11 23	pegloticase)
T5	tradename 146 155	KRYSTEXXA
T7	tradename 219 239	KRYSTEXXA KRYSTEXXA
T9	nanoparticle 241 253	pegloticase)
T11	routeofadministration 269 280	intravenous
T13	fdaapprovaldate 313 317	2010
T15	adversereaction 328 339	ANAPHYLAXIS
T17	adversereaction 344 362	INFUSION REACTIONS
T19	adversereaction 427 438	Anaphylaxis
T21	adversereaction 443 461	infusion reactions
T23	tradename 525 534	KRYSTEXXA
T25	tradename 548 557	KRYSTEXXA
T27	adversereaction 652 663	anaphylaxis
T29	adversereaction 668 687	infusion reactions.
T31	co-administereddrug 728 742	antihistamines
T33	co-administereddrug 747 763	corticosteroids.
T35	adversereaction 840 851	anaphylaxis
T37	tradename 876 889	KRYSTEXXA. 
T39	adversereaction 1186 1197	Anaphylaxis
T41	adversereaction 1238 1255	Infusion Reaction
T43	tradename 1343 1352	KRYSTEXXA
T45	nanoparticle 1354 1366	pegloticase)
T47	surfacecoating 1372 1381	PEGylated
T49	activeingredient 1382 1417	uric acid specific enzyme indicated
T51	indication 1439 1451	chronic gout
T53	tradename 1542 1551	KRYSTEXXA
T55	dose 1712 1716	8 mg
T57	routeofadministration 1729 1740	intravenous
T59	frequency 1750 1766	every two weeks.
T61	routeofadministration 1798 1809	intravenous
T63	routeofadministration 1844 1848	oral
T65	tradename 1887 1896	KRYSTEXXA
T67	co-administereddrug 2002 2016	antihistamines
T69	co-administereddrug 2021 2037	corticosteroids.
T71	adversereaction 2133 2145	anaphylaxis.
T73	tradename 2167 2176	KRYSTEXXA
T75	routeofadministration 2218 2229	intravenous
T77	dose 2444 2448	8 mg
T79	nanoparticle 2452 2463	pegloticase
T81	activeingredient 2486 2493	uricase
T83	tradename 2660 2669	KRYSTEXXA
T85	adversereaction 2909 2933	Anaphylaxis: Anaphylaxis
T87	tradename 2968 2980	KRYSTEXXA. 
T89	adversereaction 2980 2991	Anaphylaxis
T91	adversereaction 3128 3154	hypersensitivity reactions
T93	tradename 3182 3191	KRYSTEXXA
T95	adversereaction 3285 3297	anaphylaxis.
T97	co-administereddrug 3338 3352	antihistamines
T99	co-administereddrug 3357 3373	corticosteroids.
T101	adversereaction 3451 3462	anaphylaxis
T103	tradename 3487 3497	KRYSTEXXA.
T105	adversereaction 3504 3543	Infusion Reactions: Infusion reactions
T107	tradename 3578 3600	KRYSTEXXA. KRYSTEXXA
T109	adversereaction 3695 3714	infusion reactions.
T111	co-administereddrug 3754 3768	antihistamines
T113	co-administereddrug 3773 3789	corticosteroids.
T115	adversereaction 3843 3862	infusion reactions.
T117	adversereaction 3883 3900	infusion reaction
T119	adversereaction 4087 4104	infusion reaction
T121	adversereaction 4171 4183	Gout Flares:
T123	adversereaction 4199 4210	gout flares
T125	tradename 4306 4318	KRYSTEXXA. 
T127	adversereaction 4323 4333	gout flare
T129	tradename 4359 4368	KRYSTEXXA
T131	adversereaction 4396 4406	Gout flare
T133	co-administereddrug 4426 4471	non-steroidal anti-inflammatory drugs [NSAID]
T135	co-administereddrug 4475 4485	colchicine
T137	adversereaction 4632 4657	Congestive Heart Failure:
T139	tradename 4658 4667	KRYSTEXXA
T141	adversereaction 4715 4739	congestive heart failure
T143	tradename 4834 4843	KRYSTEXXA
T145	adversereaction 4865 4889	congestive heart failure
T147	tradename 5084 5101	KRYSTEXXA-treated
T149	adversereaction 5116 5127	gout flares
T151	adversereaction 5129 5147	infusion reactions
T153	adversereaction 5149 5155	nausea
T155	adversereaction 5157 5166	contusion
T157	adversereaction 5170 5180	ecchymosis
T159	adversereaction 5182 5197	nasopharyngitis
T161	adversereaction 5199 5211	constipation
T163	adversereaction 5213 5223	chest pain
T165	adversereaction 5225 5236	anaphylaxis
T167	adversereaction 5241 5250	vomiting.
T169	company 5305 5328	Savient Pharmaceuticals
T171	company 5330 5334	Inc.
T173	tradename 5360 5370	KRYSTEXXA)
T175	adversereaction 5558 5569	ANAPHYLAXIS
T177	adversereaction 5574 5592	INFUSION REACTIONS
T179	adversereaction 5778 5789	Anaphylaxis
T181	adversereaction 5795 5813	Infusion Reactions
T183	adversereaction 5819 5830	Gout Flares
T185	adversereaction 5836 5860	Congestive Heart Failure
T187	tradename 5884 5896	KRYSTEXXA 
T189	adversereaction 6496 6507	Anaphylaxis
T191	adversereaction 6512 6530	Infusion Reactions
T193	adversereaction 6596 6607	Gout Flares
T195	adversereaction 6736 6747	ANAPHYLAXIS
T197	adversereaction 6752 6770	INFUSION REACTIONS
T199	adversereaction 6772 6783	Anaphylaxis
T201	adversereaction 6788 6806	infusion reactions
T203	tradename 6870 6880	KRYSTEXXA.
T205	adversereaction 6924 6935	Anaphylaxis
T207	adversereaction 7073 7099	hypersensitivity reactions
T209	tradename 7126 7135	KRYSTEXXA
T211	adversereaction 7229 7240	anaphylaxis
T213	adversereaction 7245 7264	infusion reactions.
T215	co-administereddrug 7303 7317	antihistamines
T217	co-administereddrug 7322 7338	corticosteroids.
T219	adversereaction 7415 7426	anaphylaxis
T221	tradename 7451 7462	KRYSTEXXA. 
T223	tradename 7680 7689	KRYSTEXXA
T225	nanoparticle 7691 7703	pegloticase)
T227	surfacecoating 7709 7718	PEGylated
T229	activeingredient 7719 7744	uric acid specific enzyme
T231	indication 7776 7788	chronic gout
T233	tradename 8156 8165	KRYSTEXXA
T235	tradename 8314 8323	KRYSTEXXA
T237	dose 8346 8350	8 mg
T239	activeingredient 8352 8359	uricase
T241	routeofadministration 8381 8401	intravenous infusion
T243	tradename 8456 8465	KRYSTEXXA
T245	tradename 8529 8538	KRYSTEXXA
T247	tradename 8772 8781	KRYSTEXXA
T249	routeofadministration 9002 9013	intravenous
T251	tradename 9111 9120	KRYSTEXXA
T253	tradename 9191 9200	KRYSTEXXA
T255	tradename 9570 9579	KRYSTEXXA
T257	tradename 9609 9618	KRYSTEXXA
T259	routeofadministration 9638 9649	intravenous
T261	routeofadministration 9789 9800	intravenous
T263	tradename 9856 9865	KRYSTEXXA
T265	routeofadministration 9887 9891	oral
T267	routeofadministration 9950 9954	oral
T269	tradename 9999 10008	KRYSTEXXA
T271	adversereaction 10051 10062	anaphylaxis
T273	adversereaction 10067 10085	infusion reactions
T275	tradename 10383 10392	KRYSTEXXA
T277	routeofadministration 10434 10445	intravenous
T279	co-administereddrug 10596 10610	antihistamines
T281	co-administereddrug 10612 10628	corticosteroids)
T283	adversereaction 10654 10665	anaphylaxis
T285	adversereaction 10670 10689	infusion reactions.
T287	tradename 10702 10711	KRYSTEXXA
T289	adversereaction 10783 10794	anaphylaxis
T291	adversereaction 10799 10817	infusion reactions
T293	adversereaction 10945 10962	infusion reaction
T295	tradename 10999 11008	KRYSTEXXA
T297	tradename 11363 11372	KRYSTEXXA
T299	nanoparticle 11424 11435	pegloticase
T301	activeingredient 11487 11494	uricase
T303	tradename 11506 11515	KRYSTEXXA
T305	tradename 11622 11631	KRYSTEXXA
T307	tradename 11907 11920	KRYSTEXXA.  
T309	adversereaction 11953 11964	Anaphylaxis
T311	adversereaction 12016 12027	anaphylaxis
T313	tradename 12091 12100	KRYSTEXXA
T315	frequency 12101 12114	every 2 weeks
T317	adversereaction 12172 12180	wheezing
T319	adversereaction 12182 12208	peri-oral or lingual edema
T321	adversereaction 12213 12236	hemodynamic instability
T323	adversereaction 12254 12258	rash
T325	adversereaction 12262 12272	urticaria.
T327	routeofadministration 12348 12352	oral
T329	co-administereddrug 12353 12366	antihistamine
T331	routeofadministration 12371 12382	intravenous
T333	co-administereddrug 12383 12397	corticosteroid
T335	co-administereddrug 12405 12419	acetaminophen.
T337	adversereaction 12490 12501	anaphylaxis
T339	tradename 12593 12602	KRYSTEXXA
T341	adversereaction 12693 12705	anaphylaxis.
T343	adversereaction 12779 12790	Anaphylaxis
T345	adversereaction 12926 12952	hypersensitivity reactions
T347	adversereaction 13054 13065	anaphylaxis
T349	tradename 13090 13103	KRYSTEXXA. 
T351	adversereaction 13225 13236	anaphylaxis
T353	adversereaction 13301 13312	anaphylaxis
T355	routeofadministration 13629 13633	oral
T357	tradename 13661 13670	KRYSTEXXA
T359	tradename 13768 13777	KRYSTEXXA
T361	routeofadministration 13799 13803	oral
T363	routeofadministration 13862 13866	oral
T365	tradename 13902 13915	KRYSTEXXA.  
T367	adversereaction 13919 13937	Infusion Reactions
T369	adversereaction 13938 13944	During
T371	tradename 14052 14061	KRYSTEXXA
T373	dose 14062 14066	8 mg
T375	frequency 14067 14080	every 2 weeks
T377	tradename 14115 14124	KRYSTEXXA
T379	dose 14125 14129	8 mg
T381	frequency 14130 14143	every 4 weeks
T383	adversereaction 14201 14219	infusion reactions
T385	routeofadministration 14267 14271	oral
T387	co-administereddrug 14272 14285	antihistamine
T389	routeofadministration 14287 14298	intravenous
T391	co-administereddrug 14299 14313	corticosteroid
T393	co-administereddrug 14321 14335	acetaminophen.
T395	adversereaction 14406 14424	infusion reactions
T397	tradename 14516 14525	KRYSTEXXA
T399	adversereaction 14616 14635	infusion reactions.
T401	co-administereddrug 14673 14687	antihistamines
T403	co-administereddrug 14692 14708	corticosteroids.
T405	tradename 14710 14719	KRYSTEXXA
T407	adversereaction 14796 14813	infusion reaction
T409	tradename 15267 15276	KRYSTEXXA
T411	tradename 15374 15383	KRYSTEXXA
T413	tradename 15508 15521	KRYSTEXXA.  
T415	adversereaction 15525 15536	Gout Flares
T417	adversereaction 15537 15548	Gout flares
T419	tradename 15579 15589	KRYSTEXXA.
T421	adversereaction 15636 15647	gout flares
T423	adversereaction 15815 15825	Gout flare
T425	co-administereddrug 15845 15889	non-steroidal anti-inflammatory drug (NSAID)
T427	co-administereddrug 15893 15903	colchicine
T429	tradename 15965 15974	KRYSTEXXA
T431	tradename 16065 16074	KRYSTEXXA
T433	adversereaction 16266 16290	Congestive Heart Failure
T435	tradename 16292 16301	KRYSTEXXA
T437	adversereaction 16349 16373	congestive heart failure
T439	tradename 16501 16510	KRYSTEXXA
T441	adversereaction 16532 16556	congestive heart failure
T443	tradename 16629 16640	KRYSTEXXA 
T445	tradename 16727 16736	KRYSTEXXA
T447	tradename 16817 16826	KRYSTEXXA
T449	adversereaction 16888 16899	anaphylaxis
T451	adversereaction 16904 16923	infusion reactions.
T453	adversereaction 17183 17194	anaphylaxis
T455	tradename 17259 17268	KRYSTEXXA
T457	dose 17269 17273	8 mg
T459	frequency 17274 17287	every 2 weeks
T461	adversereaction 17320 17338	infusion reactions
T463	tradename 17402 17411	KRYSTEXXA
T465	dose 17412 17416	8 mg
T467	frequency 17417 17430	every 2 weeks
T469	adversereaction 17473 17484	gout flares
T471	tradename 17553 17562	KRYSTEXXA
T473	routeofadministration 17669 17673	oral
T475	co-administereddrug 17674 17687	antihistamine
T477	routeofadministration 17689 17700	intravenous
T479	co-administereddrug 17701 17715	corticosteroid
T481	co-administereddrug 17723 17736	acetaminophen
T483	adversereaction 17748 17759	anaphylaxis
T485	adversereaction 17764 17782	infusion reaction.
T487	co-administereddrug 17807 17844	non-steroidal anti-inflammatory drugs
T489	co-administereddrug 17848 17858	colchicine
T491	adversereaction 17892 17902	gout flare
T493	tradename 17932 17941	KRYSTEXXA
T495	tradename 18094 18103	KRYSTEXXA
T497	indication 18121 18133	chronic gout
T499	tradename 18286 18295	KRYSTEXXA
T501	dose 18296 18300	8 mg
T503	tradename 18346 18355	KRYSTEXXA
T505	dose 18356 18360	8 mg
T507	tradename 19468 19477	KRYSTEXXA
T509	tradename 19664 19676	KRYSTEXXA. 
T511	tradename 19811 19823	KRYSTEXXA. 
T513	tradename 21631 21640	KRYSTEXXA
T515	tradename 21736 21745	KRYSTEXXA
T517	tradename 21957 21966	KRYSTEXXA
T519	dose 21967 21971	8 mg
T521	tradename 21987 21996	KRYSTEXXA
T523	dose 21997 22001	8 mg
T525	tradename 22144 22153	KRYSTEXXA
T527	dose 22154 22158	8 mg
T529	tradename 22174 22183	KRYSTEXXA
T531	dose 22184 22188	8 mg
T533	tradename 22386 22396	KRYSTEXXA.
T535	tradename 22435 22436	 
T537	adversereaction 22436 22461	Congestive Heart Failure:
T539	tradename 22578 22587	KRYSTEXXA
T541	dose 22588 22592	8 mg
T543	frequency 22593 22607	every 2 weeks.
T545	tradename 22750 22759	KRYSTEXXA
T547	dose 22760 22764	8 mg
T549	frequency 22765 22778	every 2 weeks
T551	tradename 22999 23008	KRYSTEXXA
T553	dose 23009 23012	8mg
T555	frequency 23013 23026	every 2 weeks
T557	tradename 23129 23138	KRYSTEXXA
T559	tradename 23178 23187	KRYSTEXXA
T561	adversereaction 23214 23224	Gout flare
T563	dose 23226 23230	8 mg
T565	frequency 23231 23244	every 2 weeks
T567	adversereaction 23291 23308	Infusion reaction
T569	adversereaction 23326 23343	Nausea Contusionb
T571	adversereaction 23347 23358	Ecchymosisb
T573	adversereaction 23391 23406	Nasopharyngitis
T575	adversereaction 23422 23434	Constipation
T577	adversereaction 23450 23460	Chest Pain
T579	adversereaction 23476 23487	Anaphylaxis
T581	adversereaction 23503 23511	Vomiting
T583	adversereaction 23798 23807	contusion
T585	adversereaction 23811 23821	ecchymosis
T587	tradename 23952 23961	KRYSTEXXA
T589	frequency 23962 23975	every 2 weeks
T591	tradename 24070 24082	KRYSTEXXA. 
T593	nanoparticle 24161 24180	pegloticase-induced
T595	adversereaction 24350 24368	infusion reactions
T597	tradename 24446 24455	KRYSTEXXA
T599	frequency 24456 24469	every 2 weeks
T601	nanoparticle 24955 24966	pegloticase
T603	tradename 25091 25100	KRYSTEXXA
T605	surfacecoating 25199 25202	PEG
T607	tradename 25639 25651	KRYSTEXXA. 
T609	tradename 25675 25684	KRYSTEXXA
T611	tradename 25852 25861	KRYSTEXXA
T613	nanoparticle 25919 25930	Pegloticase
T615	dose 25972 25973	0
T617	dose 25975 25976	5
T619	dose 25978 25980	10
T621	dose 25982 25993	or 40 mg/kg
T623	frequency 25994 26006	twice weekly
T625	routeofadministration 26014 26025	intravenous
T627	dose 26167 26171	8 mg
T629	dose 26173 26184	0.133 mg/kg
T631	frequency 26210 26223	every 2 weeks
T633	tradename 26498 26507	KRYSTEXXA
T635	tradename 26582 26591	KRYSTEXXA
T637	tradename 26733 26742	KRYSTEXXA
T639	dose 26743 26747	8 mg
T641	frequency 26748 26761	every 2 weeks
T643	tradename 27269 27278	KRYSTEXXA
T645	dose 27279 27283	8 mg
T647	frequency 27284 27297	every 2 weeks
T649	tradename 27438 27447	KRYSTEXXA
T651	routeofadministration 27525 27536	intravenous
T653	dose 27545 27550	12 mg
T655	activeingredient 27554 27561	uricase
T657	tradename 27755 27764	KRYSTEXXA
T659	nanoparticle 27766 27778	pegloticase)
T661	activeingredient 27784 27809	uric acid specific enzyme
T663	surfacecoating 27821 27830	PEGylated
T665	activeingredient 27887 27900	urate oxidase
T667	activeingredient 27902 27910	uricase)
T669	activeingredient 27975 27982	Uricase
T671	surfacecoating 28011 28050	monomethoxypoly(ethylene glycol) [mPEG]
T673	molecularweight 28052 28058	10 kDa
T675	molecularweight 28205 28211	34 kDa
T677	nanoparticle 28258 28269	pegloticase
T679	activeingredient 28271 28288	tetrameric enzyme
T681	surfacecoating 28303 28308	mPEG)
T683	molecularweight 28326 28334	540 kDa.
T685	tradename 28336 28345	KRYSTEXXA
T687	routeofadministration 28362 28373	intravenous
T689	tradename 28385 28394	KRYSTEXXA
T691	nanoparticle 28454 28465	pegloticase
T693	tradename 28497 28506	KRYSTEXXA
T695	nanoparticle 28508 28520	pegloticase)
T697	tradename 28599 28608	KRYSTEXXA
T699	dose 28618 28622	8 mg
T701	activeingredient 28626 28633	uricase
T703	molecularweight 28666 28672	10 kDa
T705	surfacecoating 28673 28678	mPEG)
T707	inactiveingredient 28688 28740	Disodium Hydrogen Phosphate Dihydrate (Na2HPO4 2H2O)
T709	inactiveingredient 28750 28772	Sodium Chloride (NaCl)
T711	inactiveingredient 28782 28843	Sodium Dihydrogen Phosphate Dihydrate (NaH2PO4 &#x20ac; 2H2O)
T713	inactiveingredient 28849 28854	Water
T715	dose 28880 28884	8 mg
T717	nanoparticle 28888 28899	pegloticase
T719	activeingredient 28904 28911	uricase
T721	tradename 28977 28986	KRYSTEXXA
T723	activeingredient 28992 29017	uric acid specific enzyme
T725	activeingredient 29041 29048	uricase
T727	tradename 29369 29378	KRYSTEXXA
T729	tradename 29429 29438	KRYSTEXXA
T731	tradename 29469 29478	KRYSTEXXA
T733	dose 29479 29483	8 mg
T735	routeofadministration 29646 29657	intravenous
T737	dose 29671 29674	0.5
T739	dose 29676 29677	1
T741	dose 29679 29680	2
T743	dose 29682 29683	4
T745	dose 29685 29695	8 or 12 mg
T747	nanoparticle 29699 29710	pegloticase
T749	indication 29731 29747	symptomatic gout
T751	dose 30100 30104	8 mg
T753	dose 30109 30115	12 mg.
T755	nanoparticle 30142 30153	Pegloticase
T757	activeingredient 30211 30218	uricase
T759	routeofadministration 30254 30265	intravenous
T761	dose 30279 30285	0.5 mg
T763	dose 30289 30294	12 mg
T765	nanoparticle 30295 30306	pegloticase
T767	indication 30327 30343	symptomatic gout
T769	nanoparticle 30377 30388	pegloticase
T771	nanoparticle 30577 30589	pegloticase.
T773	nanoparticle 30782 30793	pegloticase
T775	nanoparticle 30943 30954	pegloticase
T777	routeofadministration 31343 31354	intravenous
T779	tradename 32605 32614	KRYSTEXXA
T781	indication 32650 32662	chronic gout
T783	tradename 32866 32875	KRYSTEXXA
T785	dose 32876 32880	8 mg
T787	frequency 32881 32894	every 2 weeks
T789	frequency 32898 32911	every 4 weeks
T791	tradename 33319 33328	KRYSTEXXA
T793	tradename 34187 34196	KRYSTEXXA
T795	tradename 34467 34476	KRYSTEXXA
T797	frequency 34477 34490	every 2 weeks
T799	frequency 34579 34593	4 week regimen
T801	adversereaction 34703 34714	anaphylaxis
T803	adversereaction 34719 34737	infusion reactions
T805	dose 35002 35006	8 mg
T807	frequency 35007 35020	every 2 weeks
T809	dose 35069 35073	8 mg
T811	frequency 35074 35087	every 4 weeks
T813	dose 35157 35161	8 mg
T815	frequency 35162 35175	every 2 weeks
T817	dose 35223 35227	8 mg
T819	frequency 35228 35241	every 4 weeks
T821	tradename 35537 35546	KRYSTEXXA
T823	tradename 35838 35847	KRYSTEXXA
T825	tradename 36618 36627	KRYSTEXXA
T827	dose 36628 36632	8 mg
T829	frequency 36633 36646	every 2 weeks
T831	tradename 36648 36657	KRYSTEXXA
T833	dose 36658 36662	8 mg
T835	frequency 36663 36676	every 4 weeks
T837	tradename 36729 36738	KRYSTEXXA
T839	frequency 36789 36801	every 2 week
T841	frequency 36834 36846	every 4 week
T843	tradename 36916 36925	KRYSTEXXA
T845	routeofadministration 37020 37031	intravenous
T847	tradename 37058 37067	KRYSTEXXA
T849	tradename 37179 37188	KRYSTEXXA
T851	dose 37192 37196	8 mg
T853	tradename 37287 37296	KRYSTEXXA
T855	adversereaction 37745 37756	Anaphylaxis
T857	adversereaction 37761 37779	Infusion Reactions
T859	adversereaction 37781 37792	Anaphylaxis
T861	adversereaction 37797 37815	infusion reactions
T863	adversereaction 38045 38056	anaphylaxis
T865	adversereaction 38068 38076	wheezing
T867	adversereaction 38078 38104	peri-oral or lingual edema
T869	adversereaction 38106 38129	hemodynamic instability
T871	adversereaction 38135 38139	rash
T873	adversereaction 38143 38153	urticaria.
T875	adversereaction 38216 38233	infusion reaction
T877	adversereaction 38245 38254	urticaria
T879	adversereaction 38268 38276	erythema
T881	adversereaction 38300 38307	dyspnea
T883	adversereaction 38332 38340	flushing
T885	adversereaction 38342 38358	chest discomfort
T887	adversereaction 38360 38370	chest pain
T889	adversereaction 38376 38381	rash.
T891	tradename 38533 38543	KRYSTEXXA.
T893	tradename 38693 38702	KRYSTEXXA
T895	tradename 38759 38771	KRYSTEXXA. 
T897	tradename 38856 38865	KRYSTEXXA
T899	tradename 39264 39273	KRYSTEXXA
T901	tradename 39380 39389	KRYSTEXXA
T903	tradename 39506 39515	KRYSTEXXA
T905	company 39565 39588	Savient Pharmaceuticals
T907	company 39590 39594	Inc.
